We are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

2024年8月30日 · Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 150 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections.

Anti-infectives, specifically antifungals and antibiotics, is the key focus of Basilea’s strategy. We have successfully brought two anti-infective drugs to the market: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole).

2015年7月19日 · Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance

2024年8月13日 · Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.

2017年11月2日 · Basilea received an upfront payment of CHF 70 million and is also eligible to receive up to USD 427 million in additional payments upon achievement of pre-specified regulatory and sales milestones. In addition, Basilea will also receive royalties in the mid-teen range on Pfizer's sales.

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung

Rewarding work is typically challenging, and working at Basilea is no different. Our projects are fast-paced, complex and diverse. To meet those challenges head on, it takes people that strive to perform on the highest level and are able to develop novel, out …

2024年12月23日 · Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with …

Er weist darauf hin, dass Basilea eine Strategie entwickelt habe, Zevtera auch Patienten in den USA zur Verfügung zu stellen, dem wirtschaftlich bedeutendsten Markt für nicht-generische Antibiotika im Spitalbereich.